Search Results - "Distler O"

Clinical correlations of hypocomplementaemia in systemic sclerosis: an analysis of the EULAR Scleroderma Trial and Research group (EUSTAR) database.

Authors: Foocharoen, C Distler, O Becker, M et al.

Source: Scandinavian Journal of Rheumatology. May2012, Vol. 41 Issue 3, p243-246. 4p. 1 Chart.

Bakterielle Arthritis? Gonokokken-Infektion trotz negativen Kulturen.

Alternate Title: Septic Arthritis? Gonococcal Infection Despite Negative Bacterial Cultures.

Authors: Saur, M. Distler, O. Müller, N.

Source: Praxis (1661-8157). 9/10/2008, Vol. 97, p977-983. 7p.

Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: Results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Authors: Distler O Eich W Dokoupilova E et al.

Source: Arthritis & Rheumatism. Jan2010, Vol. 62 Issue 1, p291-300. 10p.

Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis.

Authors: Skhirtladze C Distler O Dees C et al.

Source: Arthritis & Rheumatism. May2008, Vol. 58 Issue 5, p1475-1484. 10p.

Microparticles stimulate the synthesis of prostaglandin E(2) via induction of cyclooxygenase 2 and microsomal prostaglandin E synthase 1.

Authors: Jüngel A Distler O Schulze-Horsel U et al.

Source: Arthritis & Rheumatism. Nov2007, Vol. 56 Issue 11, p3564-3574. 11p.

Differential Adherence of Osteoarthritis and Rheumatoid Arthritis Synovial Fibroblasts to Cartilage and Bone Matrix Proteins and its Implication for Osteoarthritis Pathogenesis.

Authors: Schedel, J. Wenglén, C. Distler, O. et al.

Source: Scandinavian Journal of Immunology. Nov2004, Vol. 60 Issue 5, p514-523. 10p.

Nintedanib for Systemic Sclerosis- Associated Interstitial Lung Disease.

Authors: Highland, Distler O. Gahlemann, M.

Source: New England Journal of Medicine. 6/27/2019, Vol. 380 Issue 26, p2592-2592. 1/2p.

A path to the future in scleroderma.

Authors: Distler, O. Matucci-Cerinic, M. Müller-Ladner, U. et al.

Source: Rheumatology. 2008, Vol. 47 Issue suppl_5, pv1-v1. 1p.

Criteria to select molecular targets for anti-fibrotic therapy.

Authors: Distler, J. H. W. Distler, O.

Source: Rheumatology. 2008, Vol. 47 Issue suppl_5, pv12-v13. 1p.

Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis.

Authors: Distler, J. H. W. Distler, O.

Source: Rheumatology. 2008, Vol. 47 Issue suppl_5, pv10-v11. 1p.

Mechanisms of vascular damage in SSc—implications for vascular treatment strategies.

Authors: Guiducci, S. Distler, O. Distler, J. H. W. et al.

Source: Rheumatology. 2008, Vol. 47 Issue suppl_5, pv18-v20. 1p.

Effect of imatinib mesylate (IM) on endothelial cells (EC) functions

Authors: Venalis, P. Distler, O. Akhmetshina, A. et al.

Source: Joint Bone Spine. Mar2008, Vol. 75 Issue 2, p248-248. 1p.

Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease.

Authors: Meier, C. Freiburghaus, K. Bovet, C. et al.

Source: Scientific Reports. 12/14/2020, Vol. 10 Issue 1, p1-14. 14p.

Traitement continu par nintedanib chez des patients présentant une pneumopathie interstitielle diffuse associée à la sclérodermie systémique (PID-ScS) : données à trois ans de SENSCIS-ON.

Authors: Allanore, Y. Vonk, M. Distler, O. et al.

Source: Revue du Rhumatisme. 2023 Supplement 1, Vol. 90, pA205-A206. 2p.

Differences associated with age at onset in early systemic sclerosis patients: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR) database.

Authors: Carreira, PE Carmona, L Joven, BE et al.

Source: Scandinavian Journal of Rheumatology. Jan2019, Vol. 48 Issue 1, p42-51. 10p. 5 Charts.

Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators.

Authors: Kowal-Bielecka O Kowal K Distler O et al.

Source: Arthritis & Rheumatism. Dec2005, Vol. 52 Issue 12, p3783-3791. 9p.

Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis – a randomized controlled, cross-over trial.

Authors: JANIAK, P. THUMSHIRN, M. MENNE, D. et al.

Source: Alimentary Pharmacology & Therapeutics. Nov2007, Vol. 26 Issue 9, p1259-1265. 7p. 3 Charts, 3 Graphs.

The role of endothelial cells in the vasculopathy of systemic sclerosis: A systematic review.

Authors: Mostmans, Y. Cutolo, M. Giddelo, C. et al.

Source: Autoimmunity Reviews. Aug2017, Vol. 16 Issue 8, p774-786. 13p.

Profile of gastrointestinal involvement in patients with systemic sclerosis.

Authors: Schmeiser, T. Saar, P. Jin, D. et al.

Source: Rheumatology International. Aug2012, Vol. 32 Issue 8, p2471-2478. 8p. 3 Charts, 5 Graphs.

Decreased lymphatic vessel counts in patients with systemic sclerosis: association with fingertip ulcers.

Authors: Akhmetshina A Beer J Zwerina K et al.

Source: Arthritis & Rheumatism. May2010, Vol. 62 Issue 5, p1513-1522. 10p.